Mexico’s antitrust body on Monday said it had made local approval of an asset swap between French drugmaker Sanofi and Germany’s Boehringer Ingelheim conditional on Sanofi not acquiring its peer’s cough medicines in Mexico.
Mexico’s Federal Economic Competition Commission said in a statement that a proposed merger of Sanofi and Boehringer Ingelheim assets in Mexico would give Sanofi the capacity to fix prices or restrict supplies of cough medicines.
The agency said the merger in Mexico would take away leading cough market seller Sanofi’s closest competitor and increase its market share even more over smaller competitors.
The agency, known as COFECE, said the swap would only be authorized if Sanofi did not buy three brands of cough medicine, Bisolvon, Mucosolvan and Sekretovit.
Sanofi’s bid for Boehringer’s consumer health unit is part of a $20-billion asset swap, with the German company taking over its animal health arm, that has already received approval from European Union antitrust authorities.
Full Content: Reuters
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
T-Mobile Faces Class-Action Lawsuit Over Sprint Merger After Appeal Denied
May 16, 2024 by
CPI
Google Faces Backlash Over Introduction of AI-Generated Summaries in Searches
May 16, 2024 by
CPI
CMA Launches Phase 2 Probe into AlphaTheta’s Acquisition of Serato
May 16, 2024 by
CPI
NFL Executive Escapes Testifying in High-Stakes Trial Over Televised Games
May 16, 2024 by
CPI
EU Consumers Lodge Complaint Against Chinese Retailer Temu Over Content Rules Breach
May 16, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI